Aggressive lymphoma

Aggressive lymphoma
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Lymphadenopathy, fever, night sweats, weight loss
Complications	Tumor lysis syndrome, infection, anemia
Onset	Variable, often rapid
Duration	Variable, can be chronic
Types	Diffuse large B-cell lymphoma, Burkitt lymphoma, Mantle cell lymphoma
Causes	Genetic mutations, Epstein-Barr virus, HIV
Risks	Immunosuppression, autoimmune disease, family history
Diagnosis	Biopsy, immunohistochemistry, flow cytometry
Differential diagnosis	Indolent lymphoma, reactive lymphadenopathy, infection
Prevention	None specific, manage risk factors
Treatment	Chemotherapy, radiation therapy, stem cell transplant
Medication	N/A
Prognosis	Variable, depends on type and stage
Frequency	Common
Deaths	N/A

Aggressive lymphoma refers to a group of fast-growing non-Hodgkin lymphomas that require prompt diagnosis and treatment. These lymphomas are characterized by rapid proliferation of malignant lymphocytes, leading to quickly enlarging lymph nodes and potential involvement of extranodal sites.

Types

Aggressive lymphomas include several subtypes, with the most common being:

Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL is the most prevalent form of aggressive lymphoma, accounting for approximately 30-40% of all cases. It typically presents with rapidly enlarging masses in lymph nodes or extranodal sites such as the gastrointestinal tract, central nervous system, or bone marrow.

Burkitt Lymphoma

Burkitt lymphoma, touch prep, Wright stain

Burkitt lymphoma is a highly aggressive B-cell lymphoma characterized by the translocation of the MYC oncogene. It is most commonly seen in children and young adults and is associated with Epstein-Barr virus in endemic forms.

Mantle Cell Lymphoma

Mantle cell lymphoma is a rare subtype of aggressive lymphoma that often presents with widespread disease, including lymphadenopathy, splenomegaly, and bone marrow involvement. It is characterized by the overexpression of cyclin D1 due to a translocation involving chromosomes 11 and 14.

Peripheral T-Cell Lymphoma

This is a heterogeneous group of aggressive lymphomas derived from mature T-cells. They often present with systemic symptoms such as fever, weight loss, and night sweats, along with lymphadenopathy and extranodal involvement.

Diagnosis

The diagnosis of aggressive lymphoma typically involves a combination of:

• Biopsy of affected tissue, often a lymph node, to obtain a histological diagnosis.
• Immunohistochemistry and flow cytometry to determine the specific subtype of lymphoma.
• Cytogenetic and molecular studies to identify characteristic genetic abnormalities.

Treatment

Treatment of aggressive lymphoma usually involves:

• Chemotherapy, often with regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
• Radiation therapy in certain cases, particularly for localized disease.
• Stem cell transplantation for relapsed or refractory cases.

Prognosis

The prognosis for aggressive lymphoma varies depending on the specific subtype, stage at diagnosis, and response to treatment. DLBCL, for example, has a 5-year survival rate of approximately 60-70% with appropriate therapy.

Related Pages

• Non-Hodgkin lymphoma
• Lymphoma
• Hodgkin lymphoma
• Leukemia